Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia

Seminars in Thoracic and Cardiovascular Surgery

Volumn 17, Issue 1, 2005, Pages 85-96

  Riess, Friedrich Christian ^a  

^a ALBERTINEN KRANKENHAUS   (Germany)

Author keywords

Anticoagulation; Cardiac surgery; Cardiopulmonary bypass; Heparin induced thrombocytopenia; HIT

Indexed keywords

ABCIXIMAB; ANCROD; ARGATROBAN; DANAPAROID; DESULFATOHIRUDIN; ECARIN; HEPARIN; HIRULOG; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; PHENPROCOUMON; PROSTACYCLIN; RECOMBINANT HIRUDIN; THROMBOCYTE ANTIBODY; TIROFIBAN; WARFARIN;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; DIFFERENTIAL DIAGNOSIS; DOG; DRUG CLEARANCE; DRUG HALF LIFE; DRUG UTILIZATION; EMERGENCY SURGERY; ENZYME IMMUNOASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE CARE; SURGICAL PATIENT; SWINE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 17144430067     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2004.12.008     Document Type: Review

References (84)

1. D.H. Lee T.E. Warkentin Frequency of heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 107-148
2. L.H. Edmunds Jr Blood-surface interactions during cardiopulmonary bypass J Cardiovasc Surg 8 1993 404-410
3. T.F. Slaughter T.H. LeBleu J.M. Douglas Jr et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers Anesthesiology 80 1994 520-526
4. B. Poetzsch K. Madlener Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombcytopenia 2004 Marcel Dekker New York, NY 531-551
5. T.E. Warkentin B.H. Chong A. Greinacher Heparin-induced thrombocytopenia: Towards consensus Thromb Haemost 79 1998 1-7
6. T.E. Warkentin Heparin-induced thrombocytopenia: Pathogenesis and management Br J Haematol 121 2003 535-555
7. J. Amiral F. Bridey M. Dreyfus et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia Thromb Haemost 68 1992 95-96
8. T.E. Warkentin C.P.M. Hayward L.K. Boshkov et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia Blood 84 1994 3691-3699
9. D.H. Lee T.E. Warkentin G.A. Denomme et al. A diagnostic test for heparin-induced thrombocytopenia: Detection of platelet microparticles using flow cytometry Br J Haematol 95 1996 724-731
10. T.E. Warkentin J.G. Kelton A 14-year study of heparin-induced thrombocytopenia Am J Med 101 1996 502-507
11. T.E. Warkentin Clinical picture of heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 53-106
12. T.E. Warkentin M.N. Levine J. Hirsh et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin N Engl J Med 332 1995 1330-1335
13. A.P. Hong D.J. Cook C.S. Sigouin et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia Blood 101 2003 3049-3051
14. J.T. Walls J.J. Curtis D. Silver et al. Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition Ann Thorac Surg 53 1992 787-791
15. J.T. Walls T.M. Boley J.J. Curtis et al. Heparin-induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery ASAIO J 38 1992 M574-M576
16. Y. Glock E. Szmil B. Boudjema et al. Cardiovascular surgery and heparin-induced thrombocytopenia Int Angiol 7 1988 238-245
17. R.L. Singer J.D. Mannion T.L. Bauer et al. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass Chest 104 1993 1436-1440
18. J.C. Liu B.E. Lewis L.H. Steen et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia Am J Cardiol 89 2002 979-981
19. T.E. Warkentin A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann Thorac Surg 76 2003 638-648
20. V. Kiefel Differential diagnosis of acute thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 25-52
21. T.E. Warkentin A. Greinacher Laboratory testing for heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombcytopenia 2004 Marcel Dekker New York, NY 271-311
22. T.E. Warkentin J.I. Sheppard P. Horsewood et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood 96 2000 1703-1708
23. T.E. Warkentin N.M. Heddle Laboratory diagnosis of immune heparin-induced thrombocytopenia Curr Hematol Rep 2 2003 148-157
24. C. Pouplard M.A. May S. Regina et al. Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies Blood 100 2002 16a-17a (abstract)
25. M. Trossaërt A. Gaillard P.L. Commin et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery Br J Haematol 101 1998 653-655
26. T.L. Bauer G. Arepally B.A. Konkle et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery Circulation 95 1997 1242-1246
27. B.A. Konkle T.L. Bauer G. Arepally et al. Heparin-induced thrombocytopenia: Bovine versus porcine heparin in cardiopulmonary bypass surgery Ann Thorac Surg 71 2001 1920-1924
28. J.L. Francis G.P. Palmer III R. Moroose et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery Ann Thorac Surg 75 2003 17-22
29. C. Pouplard M.A. May S. Iochmann et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia Circulation 99 1999 2530-2536
30. T.E. Warkentin J.G. Kelton Temporal aspects of heparin-induced thrombocytopenia N Engl J Med 344 2001 1286-1292
31. N. Lubenow R. Kempf A. Eichner et al. Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin Chest 122 2002 37-42
32. T.E. Warkentin G.L. Dunn I.J. Cybulsky Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia Ann Thorac Surg 72 2001 1730-1732
33. A. Koster H. Kuppe G.J. Crystal et al. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin Anesth Analg 90 2000 292-298
34. A. Greinacher N. Lubenow Recombinant hirudin in clinical practice: Focus on lepirudin Circulation 103 2001 1479-1484
35. A. Greinacher P. Eichler N. Lubenow et al. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range Blood 96 2000 846-851
36. A. Greinacher Lepirudin for the treatment of heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 397-436
37. J.M. Walenga M. Bakhos H.L. Messmore et al. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model Blood Coagul Fibrinolysis 2 1991 105-111
38. F.C. Riess B. Pötzsch I. Behr et al. Recombinant hirudin as an anticoagulant during cardiac operations: Experiments in a pig model Eur J Cardio-thorac Surg 11 1997 739-745
39. M.J. Koza J.M. Walenga J. Fareed et al. A new approach in monitoring recombinant hirudin during cardiopulmonary bypass Semin Thromb Hemost 19 1993 90-96
40. B. Pötzsch K. Madlener C. Seelig et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time Thromb Haemost 77 1997 920-925
41. A. Koster R. Hansen O. Grauhan et al. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II J Cardiothorac Vasc Anesth 14 2000 249-252
42. F.C. Riess C. Löwer C. Seelig et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man J Thorac Cardiovasc Surg 110 1995 265-267
43. F.C. Riess B. Pötzsch R. Bader et al. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open-heart surgery Eur J Cardiothorac Surg 10 1996 386-388
44. F.C. Riess B. Poetzsch G. Mueller-Berghaus Recombinant hirudin as an anticoagulant during cardiac surgery in R. Pifarré (ed) New Anticoagulants for The Cardiovascular Patient 1997 Hanley & Belfus Philadelphia, PA 197-221
45. A. Koster R. Hansen H. Kuppe et al. Recombinant hirudin as an alternative anticoagulant during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients Cardiothorac Vasc Anesth 14 3 2000 243-248
46. A. Koster M. Pasic M. Bauer et al. Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function Ann Thorac Surg 69 2000 37-41
47. A. Koster F. Merkle R. Hansen et al. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems Anesth Analg 91 2000 265-269
48. F.C. Riess B. Pötzsch K. Jäger et al. Elimination von rekombinantem Hirudin aus der Blutzirkulation mittels Hämofiltration. Untersuchungen im Schweinemodell Haemost 17 1997 200-224
49. J.R. Bartholomew Bivalirudin for treatment of heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 475-507
50. A. Koster D. Chew M. Grundel et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass Anesth Analg 96 2003 383-386
51. K. Jabr J.H. Johnson M.H. McDonald et al. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia Extra Corpor Technol 36 2 2004 174-177
52. A. Koster D. Chew M. Grundel et al. Assessment of different filter systems for extracorporeal elimination of bivalirudin: An in vitro study Anesth Analg 96 2003 1316-1319
53. J.C. Vasquez A. Vichiendilokkul S. Mahmood et al. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Ann Thorac Surg 74 2002 2177-2179
54. Z. Davis R. Anderson D. Short et al. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass Ann Thorac Surg 75 2003 264-265
55. B.D. Spiess A. DeAnda A. McCarthy et al. Off pump CABG in a patient with HIT anticoagulated with bivalirudin: A case report Anesth Analg 93 2002 SCA1-SCA112
56. A.F. Merry P.J. Raudkivi N.G. Middleton et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Ann Thorac Surg 77 2004 925-931
57. A. Koster B. Spiess D. Chew et al. Effectiveness of bivalirusin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting Am J Cardiol 93 2004 356-359
58. C.P. Henny H. ten Cate J.W. ten Cate et al. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass in dogs J Lab Clin Med 106 1985 187-196
59. D.C. Doherty T.L. Ortel N. De Bruijn et al. "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass Anesthesiology 73 1990 562-565
60. H.N. Magnani R.J.R. Beijering J.W. ten Cate et al. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia in R. Pifarre (ed) New Anticoagulants for the Cardiovascular Patient 1997 Hanley & Belfus Philadelphia, PA 487-500
61. M.J. Wilhelm C. Schmid D. Kececioglu et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172 Ann Thorac Surg 61 1996 920-924
62. S.D. Gitlin G.M. Deeb C. Yann et al. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations J Vase Surg 27 1998 568-575
63. D.G. Meuleman Orgaran (Org 10172): Its pharmacological profile in experimental models Haemostasis 22 1992 58-64
64. J.R. Kappa D. Horn C.L. Mclntosh et al. Iloprost (ZK36374), a new prostacyclin analogue, permits open cardiac surgery in patients with heparin-induced thrombocytopenia Surg Forum 36 1985 285-286
65. V.P. Addonizio Jr C.A. Fisher J.R. Kappa et al. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374) Surgery 102 1987 796-807
66. E.J. Kraenzler N.J. Starr Heparin-associated thrombocytopenia: Management of patients for open heart surgery. Case reports describing the use of iloprost Anesthesiology 69 1988 964-967
67. A. Aouifi P. Blanc V. Piriou et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Ann Thorac Surg 71 2001 678-683
68. F. Mertzlufft H. Kuppe A. Koster Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: Use of heparin and epoprostenol combined with on-line monitoring of platelet function J Cardiothorac Vasc Anesth 14 2000 304-308
69. A. Koster O. Meyer T. Fischer et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban, and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II J Thorac Cardiovasc Surg 122 2001 1254-1255
70. B.E. Lewis S.A. Johnson E.D. Grassman et al. Argatroban as an anticoagulant for coronary procedures in patients with HIT antibody in R. Pifarré (ed) New Anticoagulants for the Cardiovascular Patient 1997 Hanley & Belfus Philadelphia, PA 301-308
71. B.E. Lewis J.M. Walenga R. Pifarré Argatroban in the management of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome in R. Pifarré (ed) New Anticoagulants for the Cardiovascular Patient 1997 Hanley & Belfus Philadelphia, PA 223-229
72. B.E. Lewis M.J. Hursting Argatroban therapy in heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 437-474
73. B.E. Lewis D.E. Wallis S.D. Berkowitz et al. For the ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia Circulation 103 2001 1838-1843
74. B.E. Lewis W.H. Matthai Jr. M. Cohen et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Catheter Cardiovasc Interv 57 2002 177-184
75. K. Furukawa H. Ohteki K. Hirahara et al. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations J Thorac Cardiovasc Surg 122 2001 1255-1257
76. J.T. Edwards J.K. Hamby N.K. Worrall Successful use of Argatroban as a heparin subtitute during cardiopulmonary bypass: Heparin-induced thrombocytopenia in a high-risk cardiac surgical patient Ann Thorac Surg 75 5 2003 1622-1624
77. V.J. Zulys S.J. Teasdale E.R. Michel et al. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass Anesthesiology 71 1989 870-877
78. S.J. Teasdale V.J. Zulys T. Mycyk et al. Ancrod anticoagulation for cardipulmonary bypass in heparin-induced thrombocytopenia and thrombosis Ann Thorac Surg 48 1989 712-713
79. B. Pötzsch W.P. Klövekorn K. Madlener Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [Letter] N Engl J Med 343 2000 515
80. F.C. Riess J. Kormann B. Poetzsch Recombinant hirudin as anticoagulant during cardiopulmonary bypass Anesthesiology 93 6 2000 1551-1552
81. K.R. Campbell K.W. Mahaffey B.E. Lewis et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention J Invasive Cardiol 12 suppl F 2000 14F-19F
82. B.H. Chong H.N. Magnani Danaparoid for the treatment of heparin-induced thrombocytopenia in T.E. Warkentin A. Greinacher (eds) Heparin-induced thrombocytopenia 2004 Marcel Dekker New York, NY 371-396
83. A. Greinacher P. Eichler N. Lubenow Anaphylactic reactions with lepirudin in patients with heparin-induced thrombocytopenia (HIT) Circulation 108 2003 2062-2065
84. M. Sobel B. Adelman S. Szentpeterey et al. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism J Vasc Surg 8 1988 395-401